Table 3.
Summary of objective response rates according to underlying liver diseases in major trials.
| Study | Aetiology (Proportion) | Tx | Control | ORR (%) (Tx Arm) | ORR (%) (Control Arm) |
|---|---|---|---|---|---|
| IMbrave150 [23] | HBV (48%) | Atezolizumab + Bevacizumab | Sorafenib | 32 | 8 |
| IMbrave150 [23] | HCV (21%) | Atezolizumab + Bevacizumab | Sorafenib | 30 | 21 |
| IMbrave150 [23] | Non-viral (31%) | Atezolizumab + Bevacizumab | Sorafenib | 27 | 9 |
| CheckMate 459 [19] | HBV (31%) | Nivolumab | Sorafenib | 19 | 8 |
| CheckMate 459 [19] | HCV (23%) | Nivolumab | Sorafenib | 17 | 7 |
| CheckMate 459 [19] | Non-viral (45%) | Nivolumab | Sorafenib | 12 | 7 |
| KEYNOTE-224 [18] | HBV (21%) | Pembrolizumab | - | 24 | - |
| KEYNOTE-224 [18] | HCV (25%) | Pembrolizumab | - | 8 | - |
| KEYNOTE-224 [18] | Non-viral (55%) | Pembrolizumab | - | 30 | - |
| CheckMate 040 (dose expansion) [17] | HBV (24%) | Nivolumab | - | 14 | - |
| CheckMate 040 (dose expansion) [17] | HCV (23%) | Nivolumab | - | 20 | - |
| CheckMate 040 (dose expansion) [17] | Non-viral * (53%) | Nivolumab | - | 22 | - |
ORR: Objective response rate; Tx: Treatment; * uninfected untreated+uninfected progressor.